Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Approved for marketing × cemiplimab × 1 year × Clear all

Status

Recruiting 65 Active not recruiting 23 Not yet recruiting 18 Completed 12 Terminated 7 Withdrawn 3 Suspended 1 Enrolling by invitation 1 Approved for marketing 1

Sponsor Class

Study Type

Expanded_access 1

Sponsor

Cancer Type

Thoracic 1 Dermatologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 1 Carcinoma, Basal Cell 1

Interventions

zenocutuzumab 1 tucatinib 1 talquetamab 1 niraparib 1 futibatinib 1 erdafitinib 1 cemiplimab 1 adagrasib 1 Trastuzumab 1 TIC10 compound 1 Prednisone 1 Prednisolone 1 Capecitabine 1 Amifampridine 1 Abiraterone Acetate 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06132191 2025-11-20

Expanded Access Use of Cemiplimab in Patients With Solid Tumors

Regeneron Pharmaceuticals

Approved for marketing

DermatologicThoracic

Carcinoma, Basal Cell, Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon ⚡